Reporting of Computational Modeling Studies in Medical Device Submissions

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Document issued on: January 17, 2014

You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this document, contact Tina M. Morrison, Ph.D., (301) 796-6310, tina.morrison@fda.hhs.gov.



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of Device Evaluation
Office of Science and Engineering Laboratories

Draft - Not for Implementation

Preface

Additional Copies

Additional copies are available from the Internet. You may also send an e-mail request to dsmica@fda.hhs.gov to receive an electronic copy of the guidance or send a fax request to 301-827-8149 to receive a hard copy. Please use the document number 1807 to identify the guidance you are requesting.

Table of Contents

Introduc	ction	1
Scope		1
Outline	of the Report	2
I.	Executive Report Summary	2
II.	Background/Introduction	3
III.	System Configuration	3
IV.	Governing Equations/Constitutive Laws	4
V.	System Properties	4
VI.	System Conditions	4
VII.	System Discretization	5
VIII.	Numerical Implementation	5
IX.	Validation	5
X.	Results	6
XI.	Discussion	6
XII.	Limitations	6
XIII.	Conclusions	6
Glossary	y	7
Subject	Matter Appendix I – Computational Fluid Dynamics and Mass Transport	9
Subject	Matter Appendix II – Computational Solid Mechanics	18
Subject	Matter Appendix III – Computational Electromagnetics and Optics	28
Subject	Matter Appendix IV – Computational Ultrasound	35
Subject	Matter Appendix V – Computational Heat Transfer	40

1 2 4

5

7 8

9

6

10 11 12 13

15

16

14

Introduction

For many years, computational modeling and simulation (CM&S) studies have been used by 17 sponsors as a tool to support medical device applications. These studies have traditionally 18 been used in the areas of fluid dynamics (e.g., shear stress and stagnation calculations in 19 20 ventricular assist devices), solid mechanics (e.g., maximum stress locations in a hip implant), 21 electromagnetics and optics (e.g., radiofrequency dosimetry in magnetic resonance imaging, 22 fluence for fiber optic spectroscopy devices), ultrasound propagation (e.g., absorbed energy distribution for therapeutic ultrasound), and thermal propagation (e.g., radiofrequency and 23 laser ablation devices). The purpose of this guidance document is to provide 24 recommendations to industry on the formatting, organization, and content of reports of 25 CM&S studies that are used as valid scientific evidence to support medical device 26 27 submissions. Moreover, this guidance is also for FDA Staff, to help improve the consistency and predictability of the review of computational modeling and simulation studies and to 28

29 30

31 32 33

34 35

38

Scope 36

37

Computational modeling and simulation studies, together with bench, non-clinical in vivo, and clinical studies, are tools that can be used to evaluate the safety and effectiveness of

FDA's guidance documents, including this guidance, do not establish legally enforceable

responsibilities. Instead, guidances describe the Agency's current thinking on a topic and

should be viewed only as recommendations, unless specific regulatory or statutory

requirements are cited. The use of the word should in Agency guidances means that

better facilitate full interpretation and complete review of those studies.

something is suggested or recommended, but not required.

Reporting of Computational Modeling Studies in Medical Device Submissions

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

Draft - Not for Implementation

medical devices. In order for the CM&S studies to provide valid scientific evidence in regulatory submission, specific details need to be included in the report of the studies. In this guidance, the term "CM&S report" refers to the part of a premarket submission that provides information about a CM&S study; the term does not describe a new submission requirement.

The outline provided in this document aims to establish uniformity in reporting CM&S studies. FDA recognizes that there is a variety of CM&S modalities and specific details will vary across disciplines. Therefore, we have provided a general outline in the main body of this document and five subject matter appendices for modeling and simulation modalities that are widely used in regulatory submissions. The main body is written in general terms to capture reporting for any modality. The five appendices provide more background, structure, and specific terminology for the following subject areas:

- I. Fluid Dynamics and Mass Transport
- II. Solid Mechanics
- III. Electromagnetics and Optics
- IV. Ultrasound
- V. Heat Transfer

For multiphysics modeling, recommendations in several of these appendices may apply.

Apart from the CM&S being used to support regulatory submission, we recognize that CM&S can be part of a medical device (e.g., physiological closed-loop feedback system for ventilator), or can be the medical device (e.g., electrical source estimation software, standalone medical device intended to provide decision support). This guidance document does not address the reporting of the latter two uses of CM&S, though the overall concepts outlined in this guidance are applicable.

While verification and validation are necessary components of the report of CM&S studies, this document does not establish levels of verification and validation needed for regulatory submissions. Further, this guidance document does not address how to conduct a computational modeling or simulation study, nor does adherence to this guidance ensure that your computational modeling or simulation study is adequate or appropriate. This guidance only provides guidelines for reporting this information to FDA and highlights some common issues with models and simulations.

Outline of the CM&S Report

In the following section, we provide the recommended headings and details for a CM&S report contained within a premarket submission.

I. Executive Report Summary

- We recommend that you provide a concise and complete overview of the report of the computational modeling and/or simulation study, which includes the following:
 - Context of use of analysis (e.g., to determine the maximum stress location)

	Draft Tiot for Implementation
82	• Type of analysis (e.g., fluid dynamics and mass transport, solid mechanics,
83	electromagnetics and optics, ultrasound, heat transfer)
84	• Scope of the analysis (e.g., for a device that has multiple sizes and/or
85	configurations, discuss which sizes and/or configurations were modeled, and how
86	the computational model relates to the intended patient population)
87	 Conclusions with respect to the study context of use and how they relate to the
88	regulatory submission
89	• Keywords – we recommend that you provide up to five keywords or key phrases
90	that describe the modeling modality, the device product code ¹ , any relevant
91	materials of the device, analysis type, and if applicable, location in the body for
92	intended use. For example, you could provide the key words in the following
93	format:
94	 finite element analysis, MIH, nitinol, fatigue, aorta;
95	 radiofrequency dosimetry, OQG, cobalt chromium, magnetic resonance
96	safety, hip.
97	II. Background/Introduction
98	We recommend that you provide a brief description of the device system and intended
99	use environment. Discuss the context of use analysis, as this will dictate the relevant
100	details necessary for review.
101	III. System Configuration
102	We recommend that you provide information regarding the system configuration (e.g.,
103	the geometry of the device, the computational domain, the structure of a physiological
104	control system, the <i>in vitro</i> test that is modeled).
105	· · · · · · · · · · · · · · · · · · ·
106	A. Details
107	Describe the components of the system (e.g., device, in vivo and/or in vitro
108	environment) to be evaluated. Include images, diagrams (with appropriate scaling bar
109	or dimensions), and a brief description of the model.
110	
111	Describe the methods (e.g., image reconstruction, computer aided design (CAD))
112	used to generate the system configuration and discuss how the configuration was
113	appropriately captured for the intended analysis.
114	
115	Describe the software used to generate the system configuration (e.g., CAD software,
116	image segmentation software, control-system simulation software). State whether the
117	software is commercially available, and if not, describe the methods used to verify the
118	software. If image reconstruction was used to generate geometry, describe the
119	imaging modality.
120	

¹ For more information, please see the FDA guidance *Medical Device Classification Product Codes* issued on

http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm285317.htm.

121	B. Assumptions, simplifications, and rationale
122	Describe and provide a rationale for the assumptions and simplifications used to
123	generate the system configuration as compared to the actual device and environment.
124	If appropriate, provide a clinical rationale for the in vivo/in vitro models (e.g., size,
125	disease state, mathematical convenience versus clinical relevance).
126	IV. Governing Equations/Constitutive Laws
127	We recommend that you provide information regarding the governing equations and/or
128	constitutive laws used to perform the computational analysis.
129	A Details
130	A. Details
131	Provide the governing equations/constitutive laws for the system.
132	D. Assumetions simulifications and nationals
133	B. Assumptions, simplifications, and rationale
134 135	Describe and provide a rationale for the assumptions and simplifications of the governing equations/constitutive laws chosen to represent the system.
136	V. System Properties
137	We recommend that you provide information regarding the biological, chemical, and
138	physical properties of the system.
139	
140	A. Details
141	Describe all system properties used in the analysis. These might include biological
142	materials (e.g., cells, tissues, organs) and/or processes (e.g., cell signals), and/or states
143	(e.g., diseased, healthy), chemical properties, and physical properties that define the
144	materials and/or process characteristics. Provide the parameters that define the
145	material characteristics (e.g., biological, physical, chemical), and their variability, if
146	applicable.
147	
148	B. Assumptions, simplifications, and rationale
149	Describe and provide a rationale for the assumptions and simplifications used to
150	determine the system properties. Identify the source of biological, chemical, and
151	physical properties (e.g., literature, in vivo, ex vivo, in vitro testing).
152	VI. System Conditions
153	We recommend that you provide information regarding the conditions that were imposed
154	on the system. These might include, but are not limited to, the boundary and loading
155	conditions, initial conditions, and other constraints that control the system.
156	
157	A. Details
158	Describe the system conditions imposed on the model and their variability, if
159	applicable. If appropriate, provide a graphical representation of the conditions,
160	depicting how they are applied to the system.
161	
162	B. Assumptions, simplifications, and rationale

163	Describe and provide a rationale for the assumptions and simplifications used to
164 165	determine the conditions applied on the system. Provide appropriate documentation (e.g., literature, test reports, clinical data, medical imaging data).
166	VII. System Discretization
167 168	We recommend that you provide information regarding the discretization and refinement techniques applied to the system for solving it numerically.
169 170	A. Details
171 172	Describe the system discretization methods and how they were applied to the computational domain. Describe the methodology (e.g., mesh refinement study) used
173 174	to verify suitably resolved computational domain. If applicable, provide a representative image of the discretization in the areas of interest of the computational
175 176	domain. Report the criteria used to determine that the discretization was sufficient to resolve the physics of interest.
177	D. Aggreentions simplifications and nationals
178 179	B. Assumptions, simplifications, and rationale Describe and provide a rationale for the assumptions and simplifications used to
180	discretize the computational domain.
181	VIII. Numerical Implementation
182 183	We recommend that you provide information regarding the numerical implementation strategy that yielded the solution to the governing equations.
184	
185	A. Details
186	Describe the numerical implementation methodology and/or numerical solver
187 188	employed to yield the solution to the governing equation. Explain the verification process used to ensure the governing equations were solved correctly. State the
189 190	solver parameters (e.g., tolerance, relaxation) and convergence criteria.
191	B. Assumptions, simplifications, and rationale
192	Describe and provide a rationale for the assumptions and simplifications used to
193	determine the solver and associated parameters.
194	IX. Validation
195	We recommend that you provide information regarding the methods employed to validate
196 197	the computational model.
198	A. Details
199	Describe the method used to assess the accuracy of the computational model (e.g., in
200	vivo, ex vivo or in vitro comparator). Provide sufficient details that describe how the
201	measurements were taken from the comparator and used to assess the accuracy of the
202	numerical output.
203	
204	B. Assumptions, simplifications, and rationale

205 206 207	Describe and provide the rationale for the assumptions and simplifications of the method (e.g., <i>in vivo</i> , <i>ex vivo</i> or <i>in vitro</i> test) used to validate the computational model. Explain the difference between the measured and model values, and discuss
208	its significance with respect to the purpose of the analysis.
209	X. Results
210	We recommend that you present the quantitative results from the computational modeling
211	study. Provide the results with sufficient level of details, including labels and legends.
212	The results may be presented in more than one format (e.g., table, graph, plot).
213	XI. Discussion
214	We recommend that you discuss how the results from the modeling study relate to the
215	context of use, and if appropriate, the clinical relevance and how the results compare with
216	experimental and literature results.
217	XII. Limitations
218	We recommend that you provide details regarding how the assumptions/simplifications
219	described in the previous sections might affect the output of the computational model, the
220	interpretation of the results, and the relevance to the purpose of the study. Describe the
221	outcomes and implications of all the available uncertainty analyses performed on the
222	system properties and conditions.
223	XIII. Conclusions
224	We recommend that you summarize the computational study with respect to the purpose
225	of the study and how the study relates to the regulatory submission.
226	

227	Glossary
228	We have provided the following definitions to explain the terminology used in this guidance
229	document.
230	
231	Accuracy: the difference between a parameter, variable or derived quantity (or a set of
232	parameters or variables) within a model, simulation, or experiment and the true value or the
233	assumed true value.
234	
235	Analysis: any post-processing or interpretation of the individual values, arrays, files of data,
236	or suites of executions resulting from a simulation.
237	
238	Computational model: the numerical implementation of the mathematical model performed
239	by a means of a computer.
240	
241	Constitutive law: an expression which describes the relationship between biological,
242	chemical or physical quantities for a specific material or substance under external stimuli
243	(e.g., Hooke's Law).
244	
245	Context of use: the purpose or intended use of the computational model and/or simulation
246	study.
247	
248	Convergence analysis: the process of ensuring the solution resolves the physics of interest
249	and the variation of the solution remains within a pre-specified range as the discretization is
250	refined.
251	
252	Governing equation: the mathematical relationship that describes the phenomena of
253	interest.
254	
255	Mathematical model: the mathematical equations, boundary values, initial conditions, and
256	modeling data needed to describe the conceptual model.
257	
258	Model: a description or representation of a system, entity, phenomena, or process (adapted
259	from Banks, J., ed. (1998). Handbook of Simulation. New York: John Wiley & Sons). Any
260	data that go into a model are considered part of the model. Models may be mathematical,
261	physical, or logical representations of a system, entity, phenomenon, or process. Models can
262	be used by simulation to predict a future state, if so desired.
263	
264	Simulation: the imitation of the characteristics of a system, entity, phenomena, or process
265	using a computational model.
266	Subject mottom a particular technical discipline avetam or process recording commutational
267	Subject matter: a particular technical discipline, system, or process regarding computational
268	modeling methodologies.
269	

System discretization: the division of the computational domain of the system into discrete

271	parts for numerical implementation.
272	
273	Uncertainty: the estimated amount or percentage by which an observed or calculated value
274	may differ from the true value (The American Heritage Dictionary of the English Language,
275	4th ed.).
276	
277	Validation: The process of determining the degree to which a model or a simulation is an
278	accurate representation of the real world from the perspective of the intended uses of the
279	model or the simulation (American Society of Mechanical Engineering Verification
280	&Validation Guide – ASME V&V 10-1-2012).
281	
282	Verification: The process of determining that a computational model accurately represents
283	the underlying mathematical model and its solution from the perspective of the intended uses
284	of modeling and simulation (American Society of Mechanical Engineering Verification
285	&Validation Standard – ASME V&V 20-2009).
286	

287 288 289	Subject Matter Appendix I – Computational Fluid Dynamics and Mass Transport
290291292293294	For questions regarding this appendix, contact Sandy Stewart, Ph.D., (301) 796-2581, sandy.stewart@fda.hhs.gov.
295	Introduction/Scope of the Appendix
296 297 298 299 300 301 302	The purpose of this appendix is to provide recommendations on the formatting, organization, and content of reports for computational fluid mechanics and mass transport modeling and simulation studies in medical device regulatory submissions. Moreover, this guidance is for FDA Staff, to help improve the consistency and predictability of the review of computational modeling studies and to better facilitate full interpretation and complete review of those studies.
303 304 305 306	Specific examples provided in this appendix, such as output metrics, are only examples and should not be considered as requirements or recommendations for the type of validation to complete.
307	Outline of the Report
308 309	In the following section, we provide an outline for reporting the details of your computational modeling and simulation study.
310 311 312 313 314 315	 I. Executive Report Summary We recommend that you provide a concise and complete overview of the report of the computational modeling and/or simulation study, which includes the following: Briefly summarize the purpose and scope of the analysis, as well as the rationale for choosing the modeling approach as opposed to other approaches (e.g.,
316 317 318 319 320	 experiment). Briefly summarize the type(s) of analysis(es) conducted in the computational modeling study (e.g., fluid mechanics, diffusion, diffusion/convection). Briefly summarize the model, including geometry, material properties, and boundary/initial conditions.
321 322 323 324	 If the device has multiple sizes and/or configurations, provide a rationale for the sizes and configurations of the device system evaluated and not evaluated. State whether the analysis code/software is commercially available, open source, or user developed.

Draft - Not for Implementation

- Discuss the simulation results (and experimental validation) and their implications for device safety and effectiveness. If applicable, discuss the simulation results with respect to bench testing results.
 - Summarize the limitations.
 - Summarize the conclusion(s).
 - Keywords please provide up to five keywords or key phrases that describe the
 modeling modality, the device product code, any relevant materials of the device,
 analysis type and if applicable, location in the body for intended use (e.g.,
 computational fluid dynamics, NIQ, stainless steel, drug transport, coronary
 artery). For example, the following are sample keywords relevant to this subject
 matter:
 - biofluid mechanics, drug delivery, blood flow, transport, finite volume method, finite element method, pump.

II. Background/Introduction

We recommend that you state the purpose and scope of the analysis, as this will determine the relevant details necessary for review. Provide a brief description of the device, along with its intended use environment and deployment/implantation procedure. The details provided in this section should correspond to the objectives of the analysis.

III. System Geometry (System Configuration)

We recommend that you provide information regarding the system configuration (e.g., the geometry of the device, the computational domain, the structure of a physiological control system, the *in vitro* test that is modeled).

A. Details

We recommend that you describe the components of the system (e.g., device, vessel, organ, organ system) to be evaluated. Provide all relevant dimensions of the device and geometry. Include diagrams, schematics, and photos as needed.

Describe methods/ software (e.g., image reconstruction, CAD) used to generate the geometry in order to demonstrate that the configuration was captured appropriately for the intended analysis. In particular, describe any scaling or similarities (e.g., geometric and dynamic similarity).

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for the assumptions and simplifications used to generate the system configuration as compared to the actual device and environment.

For example, if the entire device system was not modeled or if simplifications were made to the geometry, provide a rationale for the system geometry that was analyzed (e.g., the use of symmetry, only a portion of device, or representative inlet and outlet geometries), including the following:

• Describe any differences between the model and the actual configuration.

compared to nominal dimensions.

might affect the flow regime.

370

371

372

373

Draft - Not for Implementation

Discuss how manufacturing tolerance dimensions influence the results

Describe how the inlet and outlet geometries were selected and how these

374	• If the device has unique geometric features (e.g. surface topography) that
375	might affect the analysis, then describe how those were or were not accounted
376	for in the model.
377	• Include relevant information on limitations and assumptions (e.g., scaling)
378	image resolution, smoothing, image segmentation errors, as related to the
379	geometry.
380	
381	IV. Governing Equations/Constitutive Laws
382	We recommend that you provide information regarding the governing equations and/or
383	constitutive laws used to perform the computational analysis.
384	
385	A. Details
386	Provide the governing equations/constitutive laws for the system, including the
387	following:
388	 describe the equations defining the model (e.g., Navier-Stokes equations for
389	fluid flow, Fick's equations for diffusion, Darcy's equations for porous flow);
390	• describe the constitutive relationships used in the simulation (e.g., the relation
391	between shear stress and velocity gradient for fluid flow, the relation between
392	diffusion flux and concentration gradient for diffusive flow, the relation
393	between discharge flux and pressure gradient for porous flow);
394	 describe the turbulence modeling used, if any, including any specialized wall
395	functions used; and
396	 describe any other specialized mathematical modeling used (e.g., blood
397	damage modeling).
398	
399	B. Assumptions, simplifications, and rationale
400	Describe and provide a rationale for the assumptions and simplifications of the
401	governing equations and constitutive laws chosen to represent the system, including
402	the following:
403	 describe the simplifications of the basic mathematical equations based on
404	assumptions and rationale (purpose) of the simulation being undertaken;
405	 describe the assumptions and rationale involved in simplifying the governing
406	equations (e.g., use of steady rather than unsteady flow);
407	 provide information that confirms that the constitutive model(s) captures the
408	actual behavior being modeled; and
409	 provide a rationale for the use of any turbulence model or wall functions, as
410	well as other equations used to capture additional phenomena (e.g., blood
411	damage models).
412	

V. System Properties	
We recommend that you provide information regarding the biological	, chemical, and
physical properties of the system.	
416	
417 A. Details	
Provide, preferably in a tabular form, all physical properties, coeff	ficients, and
descriptive equations used in the simulation and post processing, s	such as:
• fluid viscosity and density	
• gas solubility and diffusivity	
• diffusion and reaction coefficients of constituents	
• permeability and porosity	
• temperature dependence of properties if the simulation is r	ot isothermal
Provide a report of any testing conducted to generate the system p	
426 available.	•
427	
B. Assumptions, simplifications, and rationale	
Describe and provide a rationale for the assumptions and simplific	cations used to
determine the system properties. Identify the sources of the physi	cal properties and
coefficients adopted (e.g., literature, in vivo, ex vivo, in vitro testir	g). If literature
data are cited, discuss their applicability to the specific conditions	. If testing is
conducted to determine the parameters, then provide details regard	ling the test. If
applicable, discuss any relevant aspects of tissue physiology used	in the model (e.g.,
young versus mature, healthy versus diseased).	
436	
437 If there are uncertainties associated with the data (e.g., due to inac	
simplifications, or variations), describe the sensitivity analysis you	•
appropriate, to address the effect of the uncertainties on the simula	ation results.
440	
VI. Boundary and Initial Conditions (System Condition	
We recommend that you provide information regarding the conditions	-
on the system. These might include, but are not limited to, the bound	•
conditions, initial conditions, and other constraints that control the sys	stem.
445 446 A. Details	
	tha madal
Describe the boundary conditions (e.g., inlet and outlet, walls) of a Describe any global boundary conditions used to represent the sin	
Describe any global boundary conditions used to represent the sin terms (e.g., pressure drop, mass flow rates, revolutions per minute	
450	·)·
451 If the model was time dependent, provide the following:	
452 • state the initial conditions;	
• if applicable, describe changing boundary conditions as a f	function of time
	anenon of time
454 (e.g. function table).	
 454 (e.g., function, table); 455 • if the model was pulsatile, provide the number of initial cy 	cles modeled to

457 458 describe how time steps were determined and were deemed appropriate for the analysis (e.g., time step refinement study); and

459	 describe any unsteady model(s) employed as an adjunct to a steady model
460	using a rotating or moving frame of reference (e.g., for blood pump).
461	
462	Provide any relevant nondimensional numbers, such as:
463	Reynolds number
464	 Strouhal or Womersley number (pulsatile flows)
465	 Peclet or Sherwood number (diffusion/convection)
466	• Dean number (curved flow)
467	
468	If symmetry was used to reduce the size of the model, then describe the symmetry
469	boundary conditions.
470	
471	If a turbulence model was used, then provide the turbulence boundary conditions.
472	•
473	B. Assumptions, simplifications, and rationale
474	Describe and provide a rationale for the assumptions and simplifications used to
475	determine the conditions applied on the system. Provide appropriate documentation
476	the system conditions (e.g., literature, test reports, clinical data, medical imaging
477	data).
478	
479	In particular, describe any differences or simplifications between the simulation
480	environment and the actual environment, such as,
481	 choice of boundary conditions used;
482	 operating conditions of the simulation, especially if the simulation did not
483	cover the expected range of use of the device; and
484	• other simplifications (e.g., use of symmetry, rotating frame of reference
485	instead of unsteady simulation for centrifugal pump).
486	
487	VII. System Discretization
488	We recommend that you provide information regarding the discretization and refinement
489	techniques applied to the system for solving it numerically as outlined below.
490	
491	A. Details
492	Provide the following regarding the mesh:
493	 Describe the software used for generating the mesh.
494	• Describe the mesh in all regions of the computational domain (e.g., device,
495	fluid, surrounding tissue).
496	• Describe and provide a rationale for the quality of the mesh (e.g., element/cell
497	types, sizes, shapes, quality metrics (i.e., aspect ratios)).
498	 Discuss areas of local mesh refinement in areas of interest (e.g., areas of high
499	shear stress, recirculation zones, critical concentrations, interactions between
500	the device and the body) and provide representative images of the mesh in
501	these areas.

502	• Describe any special elements/cells used if a turbulence model (or any other
503	numerical method requiring special elements/cells) was used.
504	
505	B. Assumptions, simplifications, and rationale
506	Provide the following regarding the mesh refinement study that supports the mesh:
507	 Describe any adaptive meshing or automatic mesh refinement used.
508	 Describe the mesh refinement study, and provide representative images of the
509	meshes used in the refinement study.
510	 Discuss how the mesh sensitivity analysis was performed to justify the
511	production mesh used for the subsequent simulations, that is, to demonstrate
512	that the mesh density did not affect the numerical results.
513	 Provide a rationale for the numerical metrics (e.g., shear rates, concentration
514	gradients) chosen to establish the mesh density.
515	 Provide a rationale for the algorithm for assigning the mesh density or
516	distribution.
517	
518	VIII. Numerical Implementation
519	We recommend that you provide information regarding the numerical implementation
520	strategy that yielded the solution to the governing equations.
521	
522	A. Details
523	Describe the discretization of the equations, including:
524	• numerical method used (e.g., finite element, finite volume, finite difference);
525	• temporal discretization, if any (e.g., explicit, implicit, semi-implicit);
526	• spatial discretization (i.e., interpolation of field variables between grid points);
527	and
528	• method for interpolating from face to nodes or vice versa (e.g., upwind, power
529	law).
530	Describe the solution methods and marride the followings
531	Describe the solution methods and provide the following:
532	• solver method (e.g., Newton, multigrid);
533	• solver parameters (e.g., linear solver and tolerance, preconditioners, analytic
534	or numerical Jacobian);
535	• type of software (e.g., commercial, open-source, user-developed) and name, if
536	applicable;
537	• user-supplied subroutines/code; and
538	• convergence criteria (e.g., error method, error threshold, sampling locations
539 540	and variables used).
540 541	Describe the code verification and provide the following:
542	 comparisons to simplified systems which have an analytical solution; and
543	 sensitivity analyses of the discretization scheme and solver parameters
544 544	performed using the actual system (e.g., timestep, gridsize (grid refinement)
545	and convergence criteria (e.g., 1E 6 vs 1E 7)).
545 546	and convergence enterta (c.g., 11 0 vs 11 1)).

B. Assumptions, simplifications, and rationale

547

548

549

550

551

589

590

591

Draft - Not for Implementation

Describe and provide a rationale for the assumptions and simplifications used to

the ramifications of the particular choice (i.e., discretization errors).

determine the solver and associated parameters. For example, provide a rationale for

the discretization/solver choices made (i.e., benefits over other choices) and discuss

552 IX. **Validation** 553 We recommend that you provide information regarding the methods employed to validate 554 the computational model [1]. We recommend the following format for presenting that 555 information. 556 557 A. General Description 558 Describe, if any, the experimental or analytical comparator that was used for 559 model validation study (e.g., velocity, wall shear stress calculations, 560 hydrodynamic pressure loss). If a comparator was used, describe if the 561 comparison was made in a quantitative (preferred) or qualitative manner. 562 Describe experimental uncertainty estimates if an experimental comparison is 563 performed. 564 B. Methods 565 Describe the validation test conditions and geometry. 566 Describe the region of interest where validation(s) are performed. 567 Provide diagrams and data to support the assessment of the model. 568 Describe instrumentation and calibration. 569 If a biological process was modeled (e.g., hemolysis, platelet damage, binding 570 571 of drug in vessel tissue), then describe how the biological calculations were verified and validated. 572 C. Assumptions and Rationale 573 Describe any simplifications for experimental comparator (e.g., use of 574 surrogates when biological information is lacking). 575 Provide a rationale to support any differences between the operating and 576 boundary conditions of the comparator experiments and simulations. 577 Provide a rationale for any geometric and dynamic scaling assumptions. 578 D. Validation Study Results 579 Provide qualitative comparisons between your computational model output 580 and experimental results. For example, images that directly compare model 581 and experimental results (e.g., velocity or shear stress) can provide an overall 582 qualitative assessment of how well the model can capture relevant behavior. 583 Provide quantitative comparisons for critical areas of relevance to the goals of 584 the study [2, 3]. 585 E. Discussion 586 Discuss the degree of agreement between the computational and experimental 587 588

Discuss the relevance of your validation experiment to expected clinical

loading conditions, implications of model and experimental assumptions on

the results, limitations on the agreement between the validation model and

592 593	experiment, and the extent of predictability to your device or device-tissue model.
594 505	If predictions of behavior are given in areas that are not accessible by avperiment, provide a measure of confidence. Approximate provide a measure of confidence.
595	experiment, provide a measure of confidence.
596	X. Results
597	
598	We recommend that you present the quantitative results from the computational modeling
599	study. Provide the results with sufficient level of details, including labels and legends.
600 601	The results may be presented in more than one format (e.g., table, graph, plot).
602	Specifically, we recommend that you present the results in regions of interest graphically
	and quantitatively. Additionally, please provide the following:
603	
604	• a statement of biological and other formulations (e.g., hemolysis);
605	a description of the results in relation to the goals of the study;
606	a description of how the simulation numerically converged via residual
607	reductions and/or monitoring of some physically relevant fluid flow quantity
608	at a probe point or surface location;
609	a method to demonstrate that the basic conservation laws were obeyed;
610	• a description of how the natural development and physical character of the
611	flow was unaffected by the boundaries of the simulation;
612	 a description of any sensitivity analysis performed to determine how the
613	solution varied as a function of parameters that are not well known (e.g.,
614	parameters contained in turbulence models, boundary conditions, fluid
615	properties);
616	• if limited studies were performed, a statement that the worst-case was
617	modeled and a description of that worst case;
618	 for biological extrapolations, a description of relevant variables (e.g., shear
619	rates, exposure times, recirculation zones, drug concentrations);
620	 a description of any adverse effects of device flow on tissues or organs; and
621	 a description of acceptable performance factors based on the results.
622	
623	XI. Limitations
624	We recommend that you provide details regarding how the assumptions/simplifications
625	described in the previous sections might affect the output of the computational model and
626	simulation, the interpretation of the results, and the relevance to the purpose of the study.
627	
628	Because assumptions and simplifications are made in the generation of the model device,
629	in the performance of the simulation, and in the interpretation of the analysis, it is
630	important to describe the limitations of the use of the computational model and the
631	interpretation of the results. Therefore, we recommend that you discuss how the
632	assumptions/simplifications might affect the output of the model and simulation and the
633	interpretation of its relevance to device performance and safety.
634	
635	For example, it is important to know whether the simulation of blood flow through a
636	small gap in a blood pump was based on the nominal dimensions or whether it includes

Draft - Not for Implementation

the limits of the manufactured component tolerances. If you believe that your results are significantly dependent on the assumptions and/or simplifications in your model, you should consider performing sensitivity analyses on the computational model parameters associated with the assumptions and simplifications.

XII. Discussion/Conclusion

We recommend that you summarize the computational study with respect to the purpose of the study and how it relates to the regulatory submission (e.g., selecting the device size that is expected to perform the worst under the simulated use conditions, determining the safety factor under the clinically challenging scenario(s), establishing the loading conditions for bench testing). Discuss how the results compare with experimental results, literature results and/or prior product performances, if these results exist. Discuss the assumptions and simplifications that were made to the model and how they are expected to affect the results and interpretation of the results. Discuss the strength of your conclusions in terms of the limitations of the model that you have identified. Discuss how your results convey acceptable performance of the product *in vivo*, if applicable.

Bibliography

[1] ASME V&V20-2009, Standard for Verification and Validation in Computational Fluid Dynamics and Heat Transfer

[2] Oberkampf, W.L., Trucano, T.G., and Hirsch, C., 2004 "Verification, validation, and predictive capability in computational engineering and physics," Applied Mechanics Reviews, 57, pp. 345–384.

[3] Oberkampf W.L. and Barone M.F., 2006 "Measures of agreement between computation and experiment: Validation metrics," Journal of Computational Physics, 217, pp. 5-36.

Draft - Not for Implementation

Subject Matter Appendix II – Computational Solid Mechanics

For questions regarding this appendix, contact Jason Weaver, Ph.D., (301) 796-2504, jason.weaver@fda.hhs.gov.

Introduction/Scope of the Appendix

The purpose of this appendix is to provide recommendations on the formatting, organization, and content of reports for computational solid mechanics modeling studies in medical device regulatory submissions.

Specific examples provided in this appendix, such as output metrics, are only examples and should not be considered as requirements or recommendations for the type of validation to complete.

The scope of this appendix is limited to finite element analysis (FEA). FDA acknowledges that there are other types of computational modeling modalities that can be used to evaluate the mechanics and kinematics of medical devices. Additionally, FDA acknowledges the issues and considerations for non-finite element analyses are similar to those raised for FEA and aspects of this guidance might be applicable. However, there might be aspects of the non-FEA modalities that are distinct from FEA and might present other issues which are not addressed in this appendix but should be included in the reporting of those studies.

Outline of the Report

In the following section, we provide an outline for reporting the details of your computational modeling and simulation study.

I. Executive Report Summary

We recommend that you provide a concise, high-level overview of the entire report including the following:

696 including the followin
697 • Briefly summa
698 for choosing th

- Briefly summarize the purpose and scope of the analysis, as well as the rationale for choosing the modeling approach as opposed to other approaches (e.g., experiment).
- Briefly summarize the type(s) of analysis(es) conducted in the computational modeling study (e.g., stress or strain analysis).
- Briefly summarize the model, including geometry, material properties, and boundary conditions.
- If the device has multiple sizes and/or configurations, provide a rationale for the sizes and configurations of the device system evaluated and not evaluated.

Draft - Not for Implementation

- State whether the analysis code/software is commercially available, open source,
 or user developed.
 Discuss the simulation results (and experimental validation) and their implication
 - Discuss the simulation results (and experimental validation) and their implications for device safety and effectiveness. If applicable, discuss the simulation results with respect to bench testing results.
 - Summarize the limitations.
 - Summarize the conclusion(s).
 - Keywords please provide up to five keywords or key phrases that describe the modeling modality, the device product code, any relevant materials of the device analysis type, and if applicable, location in the body for intended use (e.g., finite element analysis, MIH, nitinol, fatigue safety factors, aorta). For example, the following are keywords relevant to this subject matter that can be used:
 - finite element analysis, stress analysis, strain analysis, safety factors, fatigue.

II. Background/Introduction

Discuss the purpose and scope of the analysis, as this will dictate the relevant details necessary for review. We recommend that you give a brief device description along with its intended use environment, deployment/implantation procedure, and patient population. The details provided in this section should correspond to the objectives of your analysis.

III. System Geometry (System Configuration)

We recommend that you provide information regarding the geometry of the device, the computational domain, or the modeled *in vitro* test.

A. Details

We recommend that you provide details regarding the device and/or tissue geometry that was modeled and the method used to create the computational representation of your geometry. This section might include CAD drawings or reconstructed digital images.

B. Assumptions, simplifications, and rationale

If you did not model the entire device, describe and provide a rationale for the portion of the device that was modeled (e.g., utilized symmetry). If the device is available in different sizes or configurations, describe which sizes or configurations were modeled and provide a rationale to support the analysis of those sizes. If your device and/or tissue has unique geometric features that might affect the analysis (e.g., surface topography) then describe how those were or were not accounted for in the model. Finally, regarding the method of construction, please include relevant information on limitations and assumptions (e.g., image resolution and smoothing) as related to the geometry.

Draft - Not for Implementation

IV. Constitutive Laws

We recommend that you provide details for all of the constitutive laws or material models used to describe the mechanical behavior of the device material(s) and, if appropriate, the surrounding biological cells/tissues/organs.

.

A. Details

Describe the stress-strain relationship (e.g., linear, hyperelastic, elastic-plastic, viscoelastic, poroelastic) of the device and/or tissue material(s). Specify the degree of anisotropy (e.g., isotropic, orthotropic) of the material(s). If appropriate, the constitutive relationships should be presented graphically and/or with equations.

Additionally, we recommend that you discuss any material non-linearities that were included in the model. For example, if the model includes plastic deformation, then we recommend that you explain the equations describing the evolution of plasticity (e.g., rate dependence, hardening) in the material. If cyclic loading was modeled, we recommend that you outline the rules governing progressive material damage (fatigue) and/or the loss of material. We recommend that you also specify any additional non-linearities, such as time-dependent behavior and superelasticity. The numerical inputs for the parameters within the constitutive model should be provided in the material properties section.

B. Assumptions, simplifications, and rationale

We recommend that you provide a rationale for the constitutive model you chose to represent the material behavior, and discuss why the assumptions of that constitutive framework are consistent with the material behavior relevant to the computational analysis. For example, if you employed linear, isotropic models, then only homogeneous, small-strain deformations should be presented, and plasticity should only be excluded if stresses in the material remain below the yield strength. We recommend that you validate the constitutive model to confirm that it adequately replicates the experimental behavior of the material and that it is implemented correctly in the computational model.

V. Material Properties (System Properties)

We recommend that you provide details regarding the material properties for the device, and if appropriate, tissue materials used in the analysis. This could include synthetic materials (e.g., stainless steel, titanium, alumina, PMMA, PLGA) and biologic materials (e.g., collagen, arterial tissue, bone, muscle, cartilage, liver).

A. Details

For each material, please provide the material inputs necessary to fully characterize the relevant mechanical behavior of the material. Some examples of important material inputs include:

- Material law coefficients
- Elastic modulus
- Ultimate tensile strength

Draft - Not for Implementation

- Fatigue life/ endurance limit
- Plateau stresses and elastic strain limits for shape memory or superelastic materials such as Nitinol
- Strain at break
- Viscoelastic properties

The inputs for the device material(s) should represent the properties of the material(s) of the final, sterilized device unless an appropriate rationale is provided. The inputs for surrounding biological materials should capture the important aspects of tissue physiology (e.g., healthy versus diseased, young versus mature). Due to the substantial variability in material properties of biological materials, we recommend that you provide a rationale for the selection of properties and describe how the variability of the properties was accounted for in the computational study.

We recommend that you discuss and provide the source for the material inputs. If the values were taken from literature, we recommend that you reference and discuss the publications. If the inputs were obtained from *ex vivo* or *in vitro* testing, provide a description of the testing, including details of the test type (e.g., uniaxial tension, 3-point bend, creep), sample condition (e.g., geometry, processing, heat treatment), protocol (e.g., loading rate, frequency, mean strain), environment (e.g., temperature, humidity, solution), and, if necessary, the method(s) used to compute the material properties from the test data. The device materials used in the testing should represent the finished product, to the extent possible, while biological materials should be taken from, or comparable to, those in the target patient population, unless rationale is provided. The testing should be conducted in an environment that reflects the in-use conditions. For material properties that were determined from *in vivo* tests or data collection (e.g., imaging, implanted sensors), we recommend that you describe the sample population, test methods, the equipment used to gather data, and post-processing performed to extract relevant material inputs.

B. Assumptions, simplifications, and rationale

We recommend that you provide a rationale for the sources of material inputs, and state any assumptions or limitations that were inherent from the sources you cited or the testing that you conducted. For example, we recommend that you discuss why inputs derived from tests conducted in water at room temperature would be as appropriate as results that were derived from testing in physiologic temperature and fluid. Finally, we recommend that you provide the numerical inputs for the parameters of the constitutive model in this section.

VI. Boundary & Initial Conditions (System Conditions)

We recommend that you provide information regarding the conditions that were imposed on the system. These might include, but are not limited to, the boundary and loading conditions, initial conditions, and other constraints that control the system.

Draft - Not for Implementation

	_	
A	Det:	aila

We recommend that you provide a complete description of the loading conditions that are imposed on the model. Please provide the step-by-step structural analysis procedure that represents the complete stress/strain history of the device. Examples include, but are not limited to, stresses/strains from manufacturing (residual), implantation, and physiologic/pathologic loading. For each analysis step, we recommend the following:

- Provide an overall schematic or diagram that clearly depicts the location and direction of the imposed boundary conditions.
- Specify the three-dimensional magnitude and direction of the applied displacements, forces, pressures, and moments.
- Describe any constraints used in the model, including the location(s) and the degrees of freedom for each fixed or free constraint.
- Provide supporting rationale that describes how each boundary condition (e.g., displacement, force, pressure, moment, constraint) represents the intended loading scenario. Some examples of loading modes include radial dilatation, torsion, bending, axial tension/compression, and temperature.
- Describe the sources and/or methods used to obtain the loading mode and magnitude (e.g., literature data, standards, imaging, other analytic methods).
- Explain how the components are expected to interact. We recommend that you provide a detailed description of the interaction (i.e., contact) between the device and other components within the model, as well as those components that self-contact (e.g., stent struts under axial compression). Describe and provide a rationale for the implementation of contact conditions in the model (e.g., frictionless, coefficient of friction, bonded).

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for all boundary and initial conditions and clearly state any assumptions and simplifications that were made.

VII. Mesh (System Discretization)

We recommend that you provide the following details regarding generation of the mesh.

- Please provide the name (including version number) of the software used to create the mesh.
- Specify the number/density of elements used in the mesh, including any mesh refinement or adaptive meshing in transition regions or regions of complex geometry. You can also include the number of nodes in the model. We recommend that you provide figures depicting the mesh at relevant scales, especially in transition regions or regions of complex geometry and regions of high stress or strain.
- State the type of element(s) selected and discuss why the selected element(s) are appropriate for the analysis performed.
- Provide details of the mesh refinement or convergence analysis to demonstrate that the results are independent of element size.

	Draft - Not for Implementation
886	 Report on the number of mesh densities used to demonstrate
887	convergence stability of the results with respect to element size.
888	 Report the results of the mesh refinement analysis in graphical or tabular
889	format and clearly identify and justify the mesh chosen for subsequent
890	analysis.
891	
892	VIII. Solver (Numerical Implementation)
893	We recommend that you provide the following details regarding the software used in the
894	numerical implementation of the analysis.
895	 Provide the name (including version number) of the software used to solve the
896	model(s).
897	 If using custom or non-commercial code, provide information on its
898	verification.
899	• If subroutines are used, provide information on verification (e.g., test case)
900	and details of implementation.
901	 Describe the type of analysis completed (e.g., static structural, vibration,
902	buckling).
903	 Provide details on the solver routine used including, at a minimum, the
904	following parameters:
905	 State whether the solver is implicit or explicit. If it is explicit, include
906	the analysis time frame and the density. If it is implicit, indicate the step
907	size and/or step increment parameters.
908	 Indicate if the solver accounted for nonlinear geometric changes.
909	 State the convergence criteria and iteration method.
910	
911	IX. Post-Processing & Results
912	We recommend that you provided the following for each analysis step:
913	• List and provide a rationale for the stress or strain measure(s) reported (e.g.,
914	component, principal, von Mises).
915	• State whether the stresses or strains were reported from integration points or
916	nodes.
917	 Provide a plot of the critical stresses or strains on a material stress-strain curve
918	to illustrate the material response being modeled (e.g., loading or unloading
919	curve of a superelastic material). Alternately, provide specific values and a
920	rationale for why this plot is not needed (e.g., linear elastic loading curve).
921	 If applicable, provide a contact map which depicts the interactions between
922	contact surfaces and discuss the results.
923	
924	We recommend that you provide the following for monotonic loading:
925	• State and provide a rationale for the failure criterion (e.g., Maximum Shear
926	Stress, Mohr-Coulomb) and provide a graphic or equation that clearly
927	demonstrates how factors of safety were calculated.
928	• Provide the values and graphically display the location(s) of critical stresses,

• For reporting safety factors:

strains, forces, or displacements.

929

931	 Provide a table that specifies the safety factors for each case (i.e.,
932	device size, loading mode(s), and analysis step).
933	 Show locations of minimum safety factor(s) on the device graphically.
934	
935	We recommend that you provide the following for fatigue evaluation:
936	 Describe the method used to calculate mean and alternating stresses/strains
937	(e.g., scalar, tensor).
938	• State whether cyclic loading results in rotations of the principal directions.
939	• Graphically display the location(s) of critical mean and alternating stresses or
940	strains.
941	• State the fatigue criterion (e.g., Goodman, Soderberg) and provide a graphic
942	or equation that clearly demonstrates how fatigue factors of safety are
943	calculated.
944	• For reporting fatigue safety factors:
945	 Provide a table that specifies the critical mean and alternating
946	stresses/strains and the resulting safety factors for each device size,
947	loading mode(s), and analysis step.
948	 Show locations of minimum safety factor(s) on the device graphically.
949	 Plot mean and/or alternating stress/strains on a point cloud graph and
950	include fatigue criterion if applicable.
951	
952	For other analysis types (e.g., vibration or buckling) we recommend that you provide all
953	relevant results including critical stresses or strains and their locations on the device as
954	well as describe any post-processing techniques used to evaluate safety and/or
955	performance.
956	
957	If multiple loading modes were modeled separately, we recommend that you provide a
958	rationale and discuss the implications of superposition of stress or strain states for each
959	loading mode (e.g., location, direction, and phase of the critical stresses or strains).
960	
961	X. Validation
962	We recommend that you provide information regarding the methods employed to validate
963	the computational model [1]. Validation of the device or device-tissue model establishes
964	the level of accuracy and predictability of the model and defines the limitations of the
965	model. The results of a validation study serve to support your choice of constitutive
966	relationship, material properties, meshing, and contact. We suggest the following format
967	for presenting that information.
968	
969	A. Scope
970	Present the scope and goal of your model validation study. The type of validation
971	study performed and the output metrics compared are at your discretion, but should
972	align with the ultimate goal of your device or device-tissue computational modeling
973	study. Specify the type of information that can be gained from the validation
974	experiment and its relationship to model predictions and accuracy.

	Draft - Not for Implementation
977	B. Methods
978	Describe the comparator (e.g., physical test, <i>in vivo</i> , literature) used for the model
979	validation study. Include information and rationale for the following items:
980	 mode of loading chosen;
981	 boundary and loading conditions including the loading and unloading
982	path, as applicable;
983	 environmental parameters within the experiment (e.g., temperature,
984	humidity); and
985	 any manufacturing processes or pre-conditioning applied to the device
986	prior to conducting the experiment. For example, if the model is designed
987	to predict safety of a nitinol cardiovascular stent, specify if the device was
988	crimped and if it was tracked through a representative anatomy prior to
989	experimental measurements.
990	
991	Describe the measuring equipment used to capture data during the experiment and its
992	level of accuracy. For example, if the validation study compares uniaxial force-
993	extension data between the model and an experiment, present the capacity of the load
994	cell used to capture force data and its accuracy.
995	
996	Describe the locations on the device or tissue where the experimental measurements
997	were acquired. For example, if your study is designed to analyze strain in a hip stem,
998	describe where strain gauges were placed to acquire the data.
999 1000	Describe the computational model that was used for comparison to experimental data.
1000	Specify computational model parameters used for the validation study such as mesh
1001	density, element type, and constitutive relationships. If the validation model
1002	parameters are different from those used in the device or device-tissue model, provide
1004	an appropriate rationale for their differences.
1005	with appropriate retrieved with derivatives.
1006	Describe the boundary and loading conditions used for the model and describe how
1007	they relate to the validation experiment. For example, the rate and magnitude of
1008	applied torsion to a pedicle screw system in the computational model should match
1009	that applied to the device mounted on a mechanical testing system.
1010	
1011	Describe the computational model output. If applicable, describe any post-processing
1012	calculations done to arrive at your output. Please also specify if the output was
1013	calculated for the entire system (e.g., reaction force/torque) or if it is calculated in a
1014	specific location (e.g., angle of flare in a proximal stent on an endovascular graft).
1015	
1016	C. Assumptions and Rationale
1017	List and discuss the assumptions for the computational model of the validation
1018	experiment (i.e., neglecting viscous behavior if you are comparing instantaneous
1019	force values).
1020	

List and discuss the simplifications for the computational model of the validation experiment. These simplifications may be geometric, such as the employment of

1021

Draft - Not for Implementation

axisymmetry in the computational model or may consist of explanations for testing device sub-components (e.g., validating the wear scar on articulating components in a total disc replacement device may not necessitate modeling of the device-bone interface).

D. Validation Study Results

Present a comparison of your computational model output and experimental results. For example, if your validation study compared the radial force generated in a stent during crimping, it might be more insightful to compare this force at several diameters between nominal and crimped rather than at the crimped diameter alone.

If applicable, present the percentage difference between your experimental result and computational model.

 Include images that directly compare model and experimental results (e.g., deformation or stress contours) as these will provide a qualitative assessment that the model is able to capture relevant behavior. This comparison is likely to be useful for large deformation problems and capturing device behavior under extreme loading conditions.

E. Discussion

Provide a discussion of the extent to which your validation model is able to capture the observed validation experimental behavior.

Include in the discussion the relevance of the validation experiment to expected clinical loading conditions, implications of model and experimental assumptions on the results, limitations on the agreement between the validation model and experiment, and the extent of predictability to the device or device-tissue model.

XI. Limitations

We recommend that you discuss the limitations of the model, which might include, but are not restricted to the following:

- Material properties
- Model geometry
- Boundary conditions
- Biological processes
- Microstructure
- Process conditions (e.g., porous coating).

We recommend that you describe the assumptions and/or simplifications noted previously and how they affect the results and interpretation as they relate to the device.

If the conclusions of the analysis are significantly dependent on the assumptions and/or simplifications in the model, we recommend that you report on a sensitivity analysis of the parameters associated with those assumptions and/or simplifications.

1069	XII. Discussion/Conclusion
1070	We recommend that you discuss the results in the context of the modeling objectives and
1071	their implications on device performance and patient safety. For example, discuss how
1072	critical stresses or strains obtained from the computational model relate to failure
1073	locations observed in bench testing and/or the potential consequences of failure at
1074	locations of minimum safety factor. Additionally, we recommend that you address the
1075	following points:
1076	 Discuss any inconsistencies between the modeling results and the modeling
1077	assumptions and simplifications.
1078	 Discuss the sensitivity of the results to variations in modeling parameters
1079	(e.g., material properties, boundary conditions, geometry).
1080	State the overall conclusions of the computational modeling study and whether the
1081	objective(s) have been met.
1082	
1083	Bibliography
1084	
1085	[1] ASME V&V10-2006, Guide for Verification and Validation in Computational Solid
1086	Mechanics
1087	
1088	

1089	Subject Matter Appendix III –
1090	Computational Electromagnetics and
	Optics
1091	Optics
1092 1093 1094 1095 1096 1097	For questions regarding this appendix, contact Leonardo Angelone, Ph.D., (301) 796-2595, leonardo.angelone@fda.hhs.gov, for computational electromagnetics or Quanzeng Wang, Ph.D., (301)796-2612, quanzeng.wang@fda.hhs.gov , for computational optics.
1098	Introduction/Scope of the Appendix
1099 1100 1101 1102 1103 1104 1105 1106	The purpose of this appendix is to provide recommendations to industry on the formatting, organization, and content of the reports for computational electromagnetic (EM) and optical modeling and simulation studies used in medical device regulatory submissions to assess (1) safety (e.g., energy deposition, temperature rise, voltages, and thermal damage induced in the human body by medical devices using EM/optical energy) and (2) performance (e.g., how internal or external EM/optical sources and physical properties of devices and tissue affect the performance of medical devices.)
1107 1108 1109 1110 1111 1112 1113	Examples of such studies include safety and performance evaluation of the following medical devices: electrophysiology monitoring devices, magnetic resonance imaging (MRI) systems, MR conditional passive or active implanted devices (e.g., orthopedic devices, stents, pacemakers, and neurostimulators), devices for radiofrequency ablation, optical coherence tomograph devices, fluorescence spectroscopy devices, laser surgery devices, and optical therapy devices.
1114	Outline of the Report
1115 1116 1117	In the following section, we provide an outline for reporting the details of your computational modeling and simulation study.
1118 1119 1120 1121 1122 1123 1124 1125 1126 1127	 I. Executive Report Summary We recommend that you provide a concise and complete overview of the report of the computational modeling and simulation study that includes the following: Purpose of the study, including any relevance/correlation to other studies (e.g., bench, clinical) for validation purposes Type of the analysis (e.g., photobiological safety, MRI safety, spectroscopy device penetration depth) Scope of the analysis (e.g., for a device that has multiple sizes or configurations, discuss what sizes or configurations were modeled, and how the computational model and simulation relates to the intended patient population)
-	· · · · · · · · · · · · · · · · · · ·

1128	 Conclusions with respect to the study purpose and how they relate to the
1129	regulatory submission.
1130	 Keywords - please provide up to five keywords or key phrases that describe the
1131	modeling modality, the device product code, any relevant materials of the device
1132	analysis type, and if applicable, location in the body for intended use (e.g.,
1133	radiofrequency dosimetry, OQG, cobalt chromium, magnetic resonance safety,
1134	hip). The following are sample keywords relevant to this subject matter that can
1135	be used:
1136	 electrophysiology, radiofrequency, optical imaging, magnetic resonance
1137	imaging, active implants, Monte Carlo simulation, and finite difference
1138	time domain.
1139	
1140	II. Background/Introduction
1141	We recommend that you provide a brief description of the device system and intended
1142	use environment. Describe the purpose of the analysis, as this will dictate the relevant
1143	details necessary for review. Introduce the background and principles of the model and
1144	simulation, and provide a rationale for why it is appropriate to apply the model to the
1145	device system.
1146	
1147	III. System Geometry (System Configuration)
1148	We recommend that you provide information regarding the device and tissue geometry
1149	that was modeled (e.g., the geometry of the device, the computational domain, the in vivo
1150	or <i>in vitro</i> test that is modeled).
1151	
1152	A. Details
1153	Describe the components of the system (e.g., device, in vivo or in vitro environment)
1154	to be evaluated. Include images, diagrams (with appropriate scaling bar or
1155	dimensions), and a brief description of the model.
1156	
1157	Describe the methods (e.g., image reconstruction, computer aided design) used to
1158	generate the system configuration and discuss how the configuration was captured
1159	appropriately for the intended analysis. If image reconstruction was used to generate
1160	geometry, describe the imaging modality.
1161	
1162	Describe the software used to generate the system configuration (e.g., computer aided
1163	design software, image segmentation software) and describe the methods used to
1164	verify the software.
1165	
1166	Describe the geometrical characteristics necessary for a comprehensive description of
1167	the methodology.
1168	
1169	Because there are different applications of computational EM and optical modeling,
1170	we have provided the following examples.
1171	

For EM simulations in MRI environment, please describe:

1172

1.

1173	• the geometrical and physical characteristics of the radiofrequency coils (e.g.,
1174	geometrical dimensions, number of rungs, number of sources, lumped
1175	elements used, if any);
1176	• the physical characteristics of the phantom/anatomical models (e.g., size,
1177	dimensions, and body composition) used in the simulations and their clinical
1178	significance with respect to the indications of use;
1179	• the landmark positions of the phantom/anatomical models with respect to the
1180	coil and their clinical significance;
1181	• the geometrical and physical characteristics of the device (e.g., material
1182	properties, path of the implant inside anatomical model) and their clinical
1183	significance.
1184	
1185	2. For optical simulations, please describe:
1186	• Geometry of the light source, including the distance and angle between the
1187	light source and tissue surface, the beam size, and beam intensity profile (e.g.,
1188	Gaussian beam). Describe whether and how the illumination takes into
1189	consideration of specific optical components, such as fiber optic probes,
1190	lenses or mirrors.
1191	 Geometry of the detector, including spatial and angular restrictions on
1192	detected light, as well as the justification for these restrictions (or lack of
1193	restrictions).
1194	• Geometry of the simulated tissue (e.g., size of simulated region, surface
1195	morphology, and tissue structures such as layers, vessels, tumors or cysts) and
1196	the rationale for implementation of this geometry (e.g., tissue types
1197	represented, layers or structures present, and simulated conditions such as
1198	normal, metaplastic or neoplastic tissue).
1199	
1200	B. Assumptions, simplifications, and rationale
1201	Describe and provide a rationale for the assumptions and simplifications used to
1202	generate the system configuration as compared to the actual device, tissue object and
1203	environment. If appropriate, provide clinical rationale for the <i>in vivo/in vitro</i> models
1204	(e.g., size, disease state, mathematical convenience versus clinical relevance).
1205	
1206	IV. Governing Equations/Constitutive Laws
1207	We recommend that you provide information regarding the governing equations and/or
1208	constitutive laws used to perform the computational analysis.
1209	A D 4 %
1210	A. Details
1211	Provide the governing equations/constitutive laws for the system.
1212	D. Aggumntions simplifications and rationals
1213	B. Assumptions, simplifications, and rationale
1214	Describe and provide a rationale for the assumptions and simplifications of the
1215	governing equations (e.g., Laplace, Maxwell, Radiative Transport) or constitutive
1216	laws chosen to represent the system. If a thermal analysis is included, please report
1217	the results as recommended in the Heat Transfer Appendix.

Draft - Not for Implementation

1	2	1	8
	2		
	2		
	2		
1	2	2	2
1	2	2	3
1	2	2	4
1	2	2	5
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
	2		
1	2	4	4
1	2	4	5
1	2	4	6
1	2	4	7
1	2	4	8
1	2	4	9
1	2	5	0
1	2	5	1
	2		
	2		
	2		
1	_		
	2		
	2		
- 1	2	Э	ŏ

1259

V. System Properties

We recommend that you provide information regarding the biological, chemical, and physical properties of the system.

A. Details

Provide the parameters used in the analysis that define the material and/or process characteristics, and their variability, if applicable. These might include properties of biological materials (e.g., cells, tissues, organs), non-biological materials (device components, implants, contrast agents), and/or processes (e.g., cell signals), such as states (e.g., diseased, healthy), biological properties, chemical properties, and physical properties.

Specifically please provide the following inputs, when appropriate for your simulation.

- For EM simulations, Provide electrical properties of the device (e.g., conductivity, permittivity), the tissue (e.g., conductivity, permittivity, anisotropy), and any relevant, nonbiological materials (e.g., air, water, high-dielectric pads surrounding the body).
- 2. For optical simulations,
 - Provide optical properties of the device (e.g., refractive index of probe surface, numerical aperture, beam convergence or divergence, focal spot size), the tissue or non-tissue object (e.g., absorption coefficient, scattering coefficient, refractive index, scattering anisotropy, quantum yield for fluorescence), and any relevant, non-biological materials (e.g., contrast agents, nanoparticles), along with their variation in space and time (e.g., different tissue components, dynamic changes due to temperature or hydration);
 - Describe any simplifications of the optical properties (e.g., phase function) for the tissue and any relevant, non-biological materials (probes, nanoparticle or dye-based contrast agents) and state whether a diffusion condition was assumed:
 - Provide the key properties of the optical radiation simulated, including the spectral distribution of irradiance, total energy and/or power, spatial intensity distribution, and angular illumination distributions;
 - State whether or not coherence, polarization and fluorescence were considered.
- 3. For simulations that also include thermal analysis,
 - Provide the physical properties of the object (tissues and non-tissue) used for the simulations (e.g., mass density, thermal conductivity, capacitance, blood perfusion rate, Arrhenius thermal damage coefficients, electrical conductivity and permittivity);
 - Specify any non-linear or coupling between EM/optical and thermal properties of the object.

Draft - Not for Implementation

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for the assumptions and simplifications used to determine the system properties. Identify the source of biological, chemical, and physical properties (e.g., literature, *in vivo*, *in vitro* testing).

For example, describe the variation of the object material (tissue or non-tissue) properties with position, direction, time, wavelength, light intensity, temperature, and thermal damage. Please describe any non-linearity of material properties incorporated in the model and whether they may affect the modeling results. Please specify whether the system properties are spatially symmetric and steady over time. Please provide a rationale for the use of the physical properties and coefficients adopted. If the properties are derived from literature data, please provide a copy of the publications and discuss their applicability to the specific study. If the properties are derived from bench testing, please provide a full and comprehensive report of the test. Please describe the sensitivity of outcome results on key parameters and provide a systematic analysis of data uncertainty in relation to system properties.

VI. System Conditions

We recommend that you provide information regarding the conditions that were imposed on the system. These might include, but are not limited to, the boundary and loading conditions, initial conditions, and other constraints that control the system.

A. Details

Describe the system conditions imposed on the model and their variability, if applicable. If appropriate, provide a graphical representation of the conditions, depicting how they are applied to the system.

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for the assumptions and simplifications used to determine the conditions applied on the system. Provide appropriate documentation (e.g., literature, test reports, clinical data, medical imaging data) to support the system conditions.

Specifically, state whether the boundary conditions of the simulations represent a true physical boundary. Please provide evidence demonstrating that boundary conditions do not cause the simulation to generate non-physical results. Moreover, where relevant, describe how the physical properties of surrounding materials between device and tissue (e.g., air, water) will affect the boundary conditions and how the boundary condition will in turn affect the simulation results.

 For simulations of optical systems with the purpose of calculating light intensity or energy delivered to human tissue, please provide information on all the assumptions made to model each optical element. For example, light intensity or energy attenuated by each optical element due to reflection, absorption, and scattering at certain wavelength or incident angle, should be specified to properly obtain light intensity and energy delivered to the human tissue.

intensity and energy delivered to

Draft - Not for Implementation

1310)
1311	

VII. System Discretization

We recommend that you provide information regarding the discretization and refinement techniques applied to the system for solving it numerically.

A. Details

Describe the system discretization methods and how they were applied to the computational domain. Describe the methodology (e.g., mesh refinement study) used to verify proper numerical discretization. If applicable, provide a representative image of the discretization in the areas of interest of the computational domain. Report the criteria used to determine that the discretization was sufficient to resolve the physics of interest.

B. Assumptions, simplifications and rationale

Describe and provide a rationale for the assumptions and simplifications used to discretize the computational domain.

VIII. Numerical Implementation

We recommend that you provide information regarding the numerical implementation strategy that yielded the solution to the governing equations.

A. Details

Describe the numerical implementation methodology (e.g., boundary element method, finite difference time domain, methods of moments, finite element method, and Monte Carlo simulation) and numerical solver employed to yield the solution to the governing equation. Explain the verification process used to ensure the governing equations were solved correctly. State the solver parameters (e.g., tolerance, relaxation) and convergence criteria, and describe any stability criteria required. For integral models (e.g., Arrhenius equation), discuss the method of numerical integration.

B. Assumptions, simplifications and rationale

Describe and provide a rationale for the assumptions and simplifications used to choose the solver and associated parameters. Specifically, please provide a rationale demonstrating that the parameters selected are sufficient to achieve a convergent solution, specify the convergence criteria and describe why it was appropriate (e.g., time-steps used for finite difference time domain; simulation stopping criteria such as number of photons for Monte Carlo simulation).

IX. Validation

We recommend that you provide information regarding the methods employed to validate the computational model [1].

Draft - Not for Implementation

A. Details

Describe the method used to assess the accuracy of the computational model (e.g., *in vivo* or *in vitro* comparator). Provide sufficient details that describe how the measurements were taken from the comparator and used to assess the accuracy of the predicted numerical output. For example, validation for RF simulations in MRI may be conducted with respect to B₁ field, validation for optical modeling might be conducted with respect to detected light intensity, and validation for optical/thermal or radiofrequency/thermal modeling might be conducted with respect to temperature or thermal damage. Please demonstrate that the error level provides sufficient accuracy for the given application. If an analytical closed-form equation is used to support the validation, please provide the source of the equation.

B. Assumptions, simplifications and rationale

Describe and provide a rationale for the assumptions and simplifications of the method used to validate the computational model. Explain the difference between the measured and predicted value, and discuss its significance with respect to the purpose of the analysis.

X. Results

We recommend that you present the quantitative results from the computational modeling study. Provide the results with sufficient level of details, including labels and legends. The results may be presented in more than one format (e.g., tables, graphs, plots).

XI. Discussion

We recommend that you discuss how the results relate to the purpose of the computational modeling study and the clinical relevance, if appropriate, and how the results compare with the experimental and literature results.

XII. Limitations

We recommend that you provide details regarding (1) how the assumptions and simplifications described in the previous sections might affect the output of the computational model and simulation, (2) the interpretation of the results, and (3) the relevance to the purpose of the study. Describe the outcomes and implications of all the available uncertainty analyses performed on the system properties and conditions.

XIII. Conclusions

We recommend that you summarize the computational study with respect to the purpose of the study and how it relates to the regulatory submission.

Bibliography

[1] IEEE 1597.1-2008 - IEEE Standard for Validation of Computational Electromagnetics Computer Modeling and Simulations

Draft - Not for Implementation

Subject Matter Appendix IV – 1401 **Computational Ultrasound** 1402 1403 For questions regarding this appendix, contact Joshua Soneson, Ph.D., (301) 796-2512 and 1404 1405 joshua.soneson@fda.hhs.gov. 1406 1407 **Introduction/Scope of the Appendix** 1408 The purpose of this appendix is to provide recommendations on the formatting, organization, 1409 and content of reports for studies in computational ultrasound in support of device 1410 1411 submissions. 1412 **Outline of the Report** 1413 In the following section, we provide an outline for reporting the details of your 1414 computational modeling and simulation study. 1415 1416 I. Executive Report Summary 1417 We recommend that you provide a concise, high-level overview of the assumptions and 1418 rationale for the methodology/modeling approach, and the following: 1419 Describe the type(s) of analysis(es) conducted in the computational modeling 1420 study (e.g., wave propagation, heat transfer, fluid flow, thermal dose) 1421 Describe the purpose of analysis, and in particular, describe any 1422 1423 relevance/correlation to bench testing for validation purposes State whether the analysis software is open-source, commercial, or developed in-1424 house 1425 Keywords - please provide up to five keywords or key phrases that describe the 1426 modeling modality, the device product code, any relevant materials of the device, 1427 1428 analysis type, and if applicable, location in the body for intended use (e.g., finite 1429 difference method, KZK, ultrasound, hystotripsy, prostate). For example, the following are sample keywords relevant to this subject matter that can be used: 1430 1431 imaging, cavitation, therapeutic ultrasound, histotripsy, acoustic radiation force impulse, Sommerfeld integral, Rayleigh integral, Westervelt, KZK. 1432 1433 II. Background/Introduction 1434 We recommend that you provide a brief device description along with its intended use 1435 1436 environment, deployment/implantation procedure and patient population. Additionally, describe the purpose and scope of the analysis, as this will dictate the relevant details 1437 1438 necessary for review. The details provided in this section should correspond to the 1439 objectives of your analysis. 1440 1441

Draft - Not for Implementation

III. System Geometry (System Configuration)

We recommend that you provide details regarding the device and/or tissue geometry that was modeled. The configuration defines the geometry of the device, computational domain and the anatomical structure included within the computational domain.

A. Details

Describe the components of the system (e.g., device, *in vivo* and/or *in vitro* environment) to be evaluated.

Regarding the ultrasound source, include images, diagrams (with appropriate scaling bar or dimensions), and a brief description of the model(s). Specifically, discuss whether the ultrasound source is a spherical bowl or phased-array transducer. If the latter, state how many elements and how are they arranged. Finally, provide the dimensions of the device and its geometry.

Regarding the anatomy, describe the methods (e.g., image reconstruction) used to generate the simulated anatomy and discuss the techniques used to demonstrate that the configuration was captured appropriately for the intended analysis, if applicable. For example, if bone is included in the computational domain, describe how it was modeled. If blood vessel are included in the computational domain, describe the blood vessels that were modeled and represented (e.g., statistically versus simulating a single representative geometry). Finally, describe any scaling or similarities used in the modeling approach.

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for the assumptions and simplifications used to generate the system configuration as compared to the actual device and environment. If the entire device system was not modeled or if simplifications were made to the geometry, then provide a rationale for the system geometry that was analyzed (e.g., use of symmetry). Describe the difference between the model and the real situation as it pertains to the purpose of the computational modeling study. For example, if bones are present, describe if the shear-wave propagation (and subsequent heating due shear-wave absorption) was modeled. Additionally, as manufacturing tolerances can affect device functionality, describe how the range of design and manufacturing

IV. Governing Equations

We recommend that you provide information regarding the governing equations used to perform the computational analysis.

tolerance dimensions influence the results compared to nominal dimensions.

A. Details

Describe the basic equations used in the simulation. Specifically, state whether the propagation model is full-wave or parabolic, and linear or nonlinear. If acoustic streaming, mechanical, and/or thermal effects are included, discuss the coupling of the system.

Draft - Not for Implementation

B. Assumptions, simplifications, and rationale 1489 Describe and provide a rationale for the assumptions and simplifications of the basic 1490 mathematical equations that were implemented for the model and simulation, 1491 1492 specifically regarding the type of propagation model employed. 1493 V. System Properties 1494 We recommend that you provide, preferably in tabular format, all physical properties, 1495 coefficients, descriptive equations used in the simulation and post processing. 1496 1497 A. Details 1498 1499 We have provided the following as an example of how to report the system properties. 1500 1501 Tissue properties 1502 **Numerical value Property** Unit Small signal sound speed Mass density Absorption Coefficient of nonlinearity Heat capacity Thermal conductivity Perfusion rate 1503 Transducer characteristics 1504 Characteristic **Numerical value** 1505 Unit Acoustic power Frequency Pressure/phase distribution 1506 1507 1508 We recommend that you indicate the dependence of properties on other variables, such as temperature, frequency, thermal dose and location, if included. 1509 1510 B. Assumptions, simplifications, and rationale 1511 Describe and provide a rationale for the assumptions and simplifications used to 1512 determine the system properties. Identify the sources of the physical properties and 1513 coefficients adopted (e.g., literature, in vivo, ex vivo, in vitro testing). 1514 1515 1516 If literature data are cited and the data are condition-specific, discuss their applicability to the model. If testing is conducted to determine the parameters, 1517 describe the test methods and results as applicable to the model. 1518 1519

Draft - Not for Implementation

If there are uncertainties associated with the data (i.e., due to accuracies, simplifications, or variations), you should perform a sensitivity analysis, if appropriate, to address the effect of the uncertainties on the simulation results.

VI. Boundary & Initial Conditions (System Conditions)

We recommend that you provide a complete description of the initial and boundary conditions that are imposed on the model. These include, but are not limited to, absorbing boundaries and transducer loading. Provide a rationale for the choice of the initial/boundary conditions and if appropriate, provide a graphical representation of the conditions, depicting how they are applied to the system.

VII. System Discretization

We recommend that you provide the following details regarding the spatial discretization.

A. Details

Describe the spatial discretization method and, if applicable, the technique used to integrate the evolution variable. If complex geometry requires the use of a non-uniform mesh, provide images/diagrams of the mesh. Additionally, indicate the details of the mesh. Specifically,

- describe and provide a rationale for the quality of the mesh (e.g., element/cell types, sizes, shapes, quality metrics (e.g., aspect ratios) and formulations chosen for the production mesh for the mesh of the analysis domain); and.
- discuss mesh refinement in areas of interest, for example, where the field changes rapidly in space.

If adaptive meshing refinement techniques were employed, then discuss the methods and provide details regarding the finished mesh.

B. Assumptions, simplifications and rationale

Describe and provide a rationale for the assumptions and simplifications used to discretize the computational domain and, if applicable, the integration scheme. Perform a convergence analysis (solution as a function of mesh density) and provide details that demonstrate that discretization adequately resolved the physics of interest.

VIII. Numerical Implementation

We recommend that you provide the following details regarding the software used in the numerical implementation of the analysis. For models using differential equations, discuss the method used to solve the discrete equations. For integral models, discuss the method of numerical integration. Provide a rationale for the choice of the methods used and possible effects on the solution. Finally, describe and provide a rationale for any techniques used to accelerate the computation, such as neglecting terms in regions where they have subleading order, adaptive stepping or variable number of harmonics.

IX. Validation

We recommend that you provide information regarding the methods employed to validate the computational model. Specifically, describe the method(s) used to assess the

Draft - Not for Implementation

accuracy of the computational model with appropriate bench methods, conserved 1565 quantities and known analytical solutions. Provide diagrams and data to support the 1566 assessment of the model. Provide details on how the measurements were taken from the 1567 1568 bench test and compared to the computational model. Discuss any differences between bench testing/known solutions and results from the computational model. 1569 1570 X. Results 1571 We recommend that you present the quantitative results from the computational modeling 1572 1573 study over the range of intended use parameters. Provide the results with a sufficient level of details, including labels and legends. The results may be presented in more than 1574 1575 one format (e.g., table, graph, plot). 1576 XI. **Discussion** 1577 We recommend that you discuss how the results relate to the purpose of the 1578 computational modeling study, and if appropriate the clinical relevance and how the 1579 1580 results compare with experimental and literature results, if these results exist. 1581 XII. Limitations 1582 Describe the assumptions/simplifications made in the model generation, simulation and 1583 analysis. Discuss how those assumptions/simplifications might affect the output of the 1584 1585 model and the interpretation of its relevance to the device and safety. Describe the outcomes and implications of all the available uncertainty analyses performed on the 1586 1587 system properties and conditions. 1588 **XIII.** Conclusions 1589 1590 We recommend that you summarize the computational study with respect to the purpose 1591

of the study and how it relates to the regulatory submission.

1595	Subject Matter Appendix V –
1596	Computational Heat Transfer
1597	•
1598 1599 1600 1601	For questions regarding this appendix, contact Joshua Soneson, Ph.D., (301) 796-2512 and joshua.soneson@fda.hhs.gov.
1602	Introduction/Scope of the Appendix
	• • •
1603 1604 1605 1606	The purpose of this appendix is to provide recommendations on the formatting, organization and content of reports for studies in computational heat transfer in support of device submissions.
1607	Outline of the Report
1608 1609 1610	In the following section, we provide an outline for reporting the details of your computational modeling and simulation study.
1611	I. Executive Report Summary
1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625	 We recommend that you provide a concise, high-level overview of the assumptions and rationale for the methodology/modeling approach, and the following: Describe the type(s) of analysis(es) conducted in the computational modeling study (e.g., radiation or conduction heat transfer, fluid flow, chemical reaction, EM or acoustic absorption) Describe the purpose of analysis, and in particular, describe any relevance/correlation to bench testing for validation purposes State whether the analysis software is open-source, commercial, or developed inhouse Keywords - please provide up to five keywords or key phrases that describe the modeling modality, the device product code, any relevant materials of the device analysis type, and if applicable, location in the body for intended use (e.g., finite difference method, MNB, heat conduction, thermal ablation, uterus). For example, the following are sample keywords relevant to this subject matter that
1626 1627 1628 1629	can be used: - thermal diffusivity, source, diffusion equation, heat capacity, radiation, conduction.
1630	II. Background/Introduction
1631	We recommend that you provide a brief device description along with its intended use
1632	environment, deployment/implantation procedure and patient population. Additionally,
1633 1634	describe the purpose and scope of the analysis, as this will dictate the relevant details necessary for review. The details provided in this section should correspond to the
1634 1635	objectives of your analysis.

Draft - Not for Implementation

1	636	
1	637	

III. System Geometry (System Configuration)

We recommend that you provide details regarding the device and/or tissue geometry that was modeled. The configuration defines the geometry of the device, computational domain and the anatomical structure included within the computational domain.

A. Details

Describe the components of the system (e.g., device, *in vivo* and/or *in vitro* environment) to be evaluated.

Regarding the heat source, include images, diagrams (with appropriate scaling bar or dimensions) and a brief description of the model(s). Additionally, provide dimensions of device and geometry.

Regarding the anatomy, describe the methods (e.g., image reconstruction) used to generate the simulated anatomy and discuss the techniques used to demonstrate that the configuration was captured appropriately for the intended analysis, if applicable. Finally, describe any scaling or similarities used in the modeling approach.

<u>Describe</u> the methods for quantifying temperature-induced bioeffects such as phase change or thermal damage.

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for the assumptions and simplifications used to generate the system configuration as compared to the actual device and environment. If the entire device system was not modeled or if simplifications were made to the geometry, then provide a rationale for the system geometry that was analyzed (e.g., use of symmetry). Describe the difference between the model and the real situation as it pertains to the purpose of the computational modeling study. Additionally, as manufacturing tolerances can affect device functionality, describe how the range of design and manufacturing tolerance dimensions influence the results compared to nominal dimensions.

IV. Governing Equations

We recommend that you provide information regarding the governing equations used to perform the computational analysis.

A. Details

 Describe the basic equations used in the simulation. Specifically, state whether materials are isotropic and if not, describe how anisotropy is addressed. Describe the coupling to other physical processes (i.e., fluid flow, heat sources in domain or on boundary) that were included in the model.

Draft - Not for Implementation

1	682	

1683

1684 1685

1686

1687

1688 1689

1690

1691 1692

1693

1694

1695

1696

1697

1698 1699

1700 1701

1702 1703

1704 1705

1706 1707

1708 1709 1710

1711 1712

1713

1714

1715

1716 1717

1718 1719

1720 1721

VII. System Discretization We recommend that you provide the following details regarding the spatial discretization.

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for the assumptions and simplifications of the basic mathematical equations that were implemented for the model and simulation, as well as the methods for quantifying thermal damage.

V. System Properties

We recommend that you provide, preferably in tabular format, all physical properties, coefficients and descriptive equations used in the simulation and post processing.

A. Details

We have provided the following as an example of how to report the system properties.

Tissue properties

Property	Numerical value	Unit
Mass density		
Heat capacity		
Thermal conductivity		
Perfusion rate		

We recommend that you indicate the dependence of properties on other variables, such as temperature, frequency, thermal damage and location, if included.

B. Assumptions, simplifications, and rationale

Describe and provide a rationale for the assumptions and simplifications used to determine the system properties. Identify the sources of the physical properties and coefficients adopted (e.g., literature, in vivo, ex vivo, in vitro testing).

If literature data are cited and the data are condition specific, discuss their applicability to the model. If testing is conducted to determine the parameters, describe the test methods and results as applicable to the model.

If there are uncertainties associated with the data (i.e., due to accuracies, simplifications or variations), perform sensitivity analysis, if appropriate, to address the effect of the uncertainties on the simulation results.

Boundary & Initial Conditions (System Conditions) VI.

We recommend that you provide a complete description of the initial and boundary conditions that are imposed on the model. Provide a rationale for the choice of the initial/boundary conditions and if appropriate, provide a graphical representation of the conditions, depicting how they are applied to the system.

Draft - Not for Implementation

1	722	
-	, 22	

A. Details

Describe the spatial discretization method and, if applicable, the technique used to integrate the evolution variable. If complex geometry requires the use of a non-uniform mesh, provide images/diagrams of the mesh. Additionally, indicate the details of the mesh. Specifically, you should:

- describe and provide a rationale for the quality of the mesh (e.g., element/cell types, sizes, shapes, quality metrics (e.g., aspect ratios) and formulations chosen for the production mesh for the mesh of the analysis domain); and.
- discuss mesh refinement in areas of interest, for example, where the field changes rapidly in space.

If adaptive meshing refinement techniques were employed, then discuss the methods and provide details regarding the finished mesh.

B. Assumptions, simplifications and rationale

Describe and provide a rationale for the assumptions and simplifications used to discretize the computational domain and, if applicable, the integration scheme. Perform a convergence analysis (solution as a function of mesh density), a stability analysis where applicable, and provide details that demonstrate that the discretization adequately resolved the physics of interest.

VIII. Numerical Implementation

We recommend that you provide the following details regarding the software used in the numerical implementation of the analysis. For models using differential equations, discuss the method used to solve the discrete equations. For integral models, discuss the method of numerical integration. Provide a rationale for the choice of the methods used and possible effects on the solution. Finally, describe and provide a rationale for any techniques used to accelerate the computation, such as neglecting terms in regions where they have subleading order, adaptive stepping, etc.

IX. Validation

We recommend that you provide information regarding the methods employed to validate the computational model. Specifically, describe the method(s) used to assess the accuracy of the computational model with appropriate bench methods, conserved quantities and known analytical solutions. Provide diagrams and data to support the assessment of the model. Provide details on how the measurements were taken from the bench test and compared to the computational model. Discuss any differences between bench testing/known solutions and results from the computational model.

X. Results

We recommend that you present the quantitative results from the computational modeling study over the range of intended use parameters. Provide the results with sufficient level of details, including labels and legends. The results may be presented in more than one format (e.g., table, graph, plot).

1767	
1768	XI. Discussion
1769	We recommend that you discuss how the results relate to the purpose of the
1770	computational modeling study, and if appropriate the clinical relevance and how the
1771	results compare with experimental and literature results, if these results exist.
1772	
1773	XII. Limitations
1774	Describe the assumptions/simplifications made in the model generation, simulation and
1775	analysis. Discuss how those assumptions/simplifications might affect the output of the
1776	model and the interpretation of its relevance to the device and safety. Describe the
1777	outcomes and implications of all the available uncertainty analyses performed on the
1778	system properties and conditions.
1779	
1780	XIII. Conclusions
1781	We recommend that you summarize the computational study with respect to the purpose
1782	of the study and how it relates to the regulatory submission.
1783	
1784	